{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:22:29Z","timestamp":1789593749402,"version":"build-2803163510"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[1998,4,1]],"date-time":"1998-04-01T00:00:00Z","timestamp":891388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1998,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The increasing emergence of penicillin-resistant and multidrug-resistant strains of\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            will create a serious therapeutic problem in coming years. Trovafloxacin is a novel naphthyridone quinolone with promising activity against\n            <jats:italic>S. pneumoniae<\/jats:italic>\n            , including penicillin-resistant strains (MIC for 90% of the isolates tested, 0.25 \u03bcg\/ml). We compared its in vivo efficacy with that of other fluoroquinolones (ciprofloxacin, temafloxacin, and sparfloxacin) and a reference beta-lactam (amoxicillin) in a model of acute experimental pneumonia. Immunocompetent Swiss mice were infected by peroral tracheal delivery of a virulent, penicillin-susceptible strain (MIC, 0.03 \u03bcg\/ml); leukopenic Swiss mice were infected with three poorly virulent, penicillin-resistant strains (MICs, 4 to 8 \u03bcg\/ml) and a ciprofloxacin-resistant strain (MIC, 32 \u03bcg\/ml). Treatments were started 6 h (immunocompetent mice) or 3 h (leukopenic mice) after infection. Doses ranging from 12.5 to 300 mg\/kg were given at 12- or 8-h intervals for 3 days. Trovafloxacin (25 mg\/kg) was the most effective agent in vivo against penicillin-susceptible and -resistant strains. Corresponding survival rates were 2- to 4-fold higher than with 50-mg\/kg sparfloxacin or temafloxacin and 8- to 16-fold higher than with 100-mg\/kg ciprofloxacin. The ratios of the area under the concentration-time curve to the MIC in serum and lung tissue were more favorable with trovafloxacin than with the other quinolones. Efficacy in vivo correlated with pharmacokinetic parameters. Trovafloxacin shows potential for the treatment of infections due to penicillin-susceptible and -resistant\n            <jats:italic>S. pneumoniae<\/jats:italic>\n            but appears to be ineffective against a ciprofloxacin-resistant strain.\n          <\/jats:p>","DOI":"10.1128\/aac.42.4.862","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:31:10Z","timestamp":1539045070000},"page":"862-867","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy of Trovafloxacin against Penicillin-Susceptible and Multiresistant Strains of\n            <i>Streptococcus pneumoniae<\/i>\n            in a Mouse Pneumonia Model"],"prefix":"10.1128","volume":"42","author":[{"given":"Jean-Pierre","family":"Be\u0301dos","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, Unite\u0301 13, Ho\u0302pital Bichat-Claude Bernard, 75877 Paris Cedex 18, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ve\u0301ronique","family":"Rieux","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, Unite\u0301 13, Ho\u0302pital Bichat-Claude Bernard, 75877 Paris Cedex 18, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Bauchet","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, Unite\u0301 13, Ho\u0302pital Bichat-Claude Bernard, 75877 Paris Cedex 18, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Muffat-Joly","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, Unite\u0301 13, Ho\u0302pital Bichat-Claude Bernard, 75877 Paris Cedex 18, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Carbon","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, Unite\u0301 13, Ho\u0302pital Bichat-Claude Bernard, 75877 Paris Cedex 18, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Azoulay-Dupuis","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale, Unite\u0301 13, Ho\u0302pital Bichat-Claude Bernard, 75877 Paris Cedex 18, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/15.1.77"},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","unstructured":"Appelbaum P. C. 1996. Emergence of resistance to antimicrobial agents in gram-positive bacteria\u2014pneumococci. Drugs 51 (Suppl. 1) : 1\u20135.","DOI":"10.2165\/00003495-199600511-00003"},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","unstructured":"Aubier M. H. Lode G. Gialdroni-Grassi G. Huchon J. Hosie N. Legakis C. Regamey S. Segev R. Vester W. J. Wijnands and N. Tolstuchow. 1996. Sparfloxacin for the treatment of community acquired pneumonia: a pooled data analysis of two studies. J. Antimicrob. Chemother. 37 (Suppl. A) : 73\u201382.","DOI":"10.1093\/jac\/37.suppl_A.73"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.2.319"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.12.2698"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.4.941"},{"key":"e_1_3_1_8_2","first-page":"984","article-title":"Relation entre virulence et r\u00e9sistance aux antibiotiques des pneumocoques.","volume":"39","author":"B\u00e9dos J. P.","year":"1991","unstructured":"B\u00e9dos J. P. Rollin O. Bouanchaud D. H. Pocidalo J. J. Relation entre virulence et r\u00e9sistance aux antibiotiques des pneumocoques. Pathol. Biol. 39 1991 984 990","journal-title":"Pathol. Biol."},{"key":"e_1_3_1_9_2","unstructured":"B\u00e9dos J. P. E. Azoulay-Dupuis P. Moine M. Muffat-Joly B. Veber J. J. Pocidalo and E. Vall\u00e9e. Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model. Relevance for drug efficacy. J. Pharm. Exp. Ther. in press."},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.60.1.111-116.1992"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.3.558"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.4.833"},{"key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jac\/35.6.869","article-title":"The in vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents.","volume":"35","author":"Child J.","year":"1995","unstructured":"Child J. Andrews J. Boswell F. Brenwald N. Wise R. The in vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. Antimicrob. Agents Chemother. 35 1995 869 876","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199651060-00010"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.2.314"},{"key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1128\/AAC.37.2.366","article-title":"In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.","volume":"37","author":"Eliopoulos G. M.","year":"1993","unstructured":"Eliopoulos G. M. Klimm K. Eliopoulos C. T. Ferraro M. J. Moellering R. C. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob. Agents Chemother. 37 1993 941 946","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1073"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199408113310607"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.10.2210"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.12.2691"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.12.2730"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0169-2607(92)90103-E","article-title":"Apis: a software model for identification, simulation and dosage regimen calculation in clinical and experimental pharmacokinetics.","volume":"38","author":"Iliadis A.","year":"1992","unstructured":"Iliadis A. Brown C. Huggins M. L. Apis: a software model for identification, simulation and dosage regimen calculation in clinical and experimental pharmacokinetics. Comput. Methods Programs Biomed. 38 1992 227 239","journal-title":"Comput. Methods Programs Biomed."},{"key":"e_1_3_1_23_2","unstructured":"Leggett J. E. S. Ebert B. Fantin and W. A. Craig. 1991. Comparative dose-effect relations at several dosing intervals for \u03b2-lactam amino-glycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand. J. Infect. Dis. 74 (Suppl.) : 179\u2013184."},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.3.542"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.1.33"},{"key":"e_1_3_1_26_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A.\n          1987\n          National Committee for Clinical Laboratory Standards\n          Villanova Pa"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.11.2615"},{"key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJM199508243330802","article-title":"Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.","volume":"333","author":"Pallar\u00e9s R.","year":"1995","unstructured":"Pallar\u00e9s R. Linar\u00e9s J. Vadillo M. Cabellos C. Manresa F. Viladrich P. F. Martin R. Gudiol F. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333 1995 474 480","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_1_29_2","unstructured":"Roussel Delvallez\n              M.\n              Wallet\n              F.\n              Caillaux\n              M.\n              Cattoen\n              C.\n              Verhaege\n              A.\n              Bonte\n              M.\n              Samaille\n              S.\n              Duhamel\n              M.\n              Fievet\n              P.\n              Tiry\n              F.\n              Reiter\n              N.\n              Descamp\n              D.\n              Marcolin\n              M.\n              Templier\n              F.\n              No\u00ebl\n              A. M.\n              Varlet\n              A.\n              Morin\n              C.\n              Courcol\n              R. J.\n          Observatoire Nord Pas de Calais: Enqu\u00eate sur la r\u00e9sistance aux antibiotiques de 1087 souches de Streptococcus pneumoniae (S. P.) isol\u00e9es dans la r\u00e9gion abstr. 80 p 6.\n          16 e R\u00e9union Interdisciplinaire de Chimioth\u00e9rapie Anti-Infectieuse\n          1996"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.10.2471"},{"key":"e_1_3_1_31_2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jac\/36.2.385","article-title":"Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.","volume":"36","author":"Teng R.","year":"1995","unstructured":"Teng R. Harris S. C. Nix D. E. Schentag J. J. Foulds G. Liston T. E. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Antimicrob. Agents Chemother. 36 1995 385 394","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.3.561"},{"key":"e_1_3_1_33_2","first-page":"524","article-title":"Le cas particulier des azalides: l\u2019antibiodiap\u00e9d\u00e8se. Donn\u00e9es exp\u00e9rimentales \u00e0 partir d\u2019un mod\u00e8le murin de pneumonie \u00e0 pneumocoque.","volume":"43","author":"Veber B.","year":"1995","unstructured":"Veber B. Pocidalo J. J. Le cas particulier des azalides: l\u2019antibiodiap\u00e9d\u00e8se. Donn\u00e9es exp\u00e9rimentales \u00e0 partir d\u2019un mod\u00e8le murin de pneumonie \u00e0 pneumocoque. Pathol. Biol. 43 1995 524 528","journal-title":"Pathol. Biol."},{"key":"e_1_3_1_34_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/jac\/37.1.77","article-title":"Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin, and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.","volume":"37","author":"Vissalli M. A.","year":"1996","unstructured":"Vissalli M. A. Jacobs M. R. Appelbaum P. C. Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin, and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology. J. Antimicrob. Chemother. 37 1996 77 84","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.4.831"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.4.862","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.42.4.862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:44:21Z","timestamp":1645479861000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.42.4.862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,4]]}},"alternative-id":["10.1128\/AAC.42.4.862"],"URL":"https:\/\/doi.org\/10.1128\/aac.42.4.862","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,4]]},"assertion":[{"value":"1997-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-02-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}